echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: The first human phase I study evaluated the application of PI3K/mTOR inhibitor GDC-0084 in patients with glioma

    Clin Cancer Res: The first human phase I study evaluated the application of PI3K/mTOR inhibitor GDC-0084 in patients with glioma

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Glioblastoma is the most common primary brain tumor.


    A total of 47 pretreated patients (2-65 mg) from 8 cohorts were included in the study.


    At 45 mg/day, the steady-state concentration of GDC-0084 exceeds the pre-clinical target concentration, producing anti-tumor activity in a xenograft model.


    In summary, the results of this study indicate that GDC-0084 exhibits typical PI3K/mTOR inhibitor-related toxicity.


     

    Original source:

     

    Patrick Y Wen, et al.


    ncbi.
    nlm.
    nih.
    gov/31937616/" target="_blank" rel="noopener">First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K / mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.